Needham Reiterates Buy on RxSight, Maintains $11 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.3%

Neg 0% Neu 89.3% Pos 0%

Needham analyst David Saxon reiterates RxSight (NASDAQ:RXST) with a Buy and maintains $11 price target.

Comments

No comments yet. Be the first!